Lifyorli and Nab-Paclitaxel Combination Receives FDA Approval for Ovarian Cancer Therapy
Published: 01 Apr 2026
Author: Precedence Research
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the development of medications for oncologic, metabolic, and neurologic diseases, has announced the U.S Food and Drug Administration approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Advancing Treatment for Platinum-Resistant Ovarian Cancer
Lifyorli (relacorilant) is the first selective glucocorticoid receptor antagonist (SGRA) approved by the FDA, a novel mode of action in oncology. This approval has been based on outcomes of the pivotal ROSELLA trial that had 381 patients and showed that the combination of relacorilant with nab-paclitaxel had a significant effect on increasing overall survival as opposed to nab-paclitaxel alone.
The mechanism of action of the therapy is competitively binding to the glucocorticoid receptor, which suppresses cortisol-induced inhibition of apoptosis, thus increasing chemotherapy efficacy. Notably, relacorilant has no effects on other steroid receptors, which adds to its positive tolerability profile. The medication is given orally during treatment cycles of chemotherapy.
Clinical specialists Dr. Rob Coleman of Texas Oncology pointed out that the treatment provides a significant survival advantage and may provide a new standard of care for these cancers that are hard to treat.
According to Precedence Research, the ovarian cancer drugs market size was calculated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.36 billion in 2026 to approximately USD 7.78 billion by 2035, expanding at a CAGR of 6.64% from 2026 to 2035, driven by the high prevalence of ovarian cancer and growing use of targeted therapies.
Industry Impact and Outlook
The approval of Lifyorli marks an innovative approach by targeting cortisol regulation in cancer therapy, opening new opportunities for glucocorticoid receptor antagonists across multiple cancer types. Ongoing investments in targeted and combination therapies suggest that advances like Lifyorli™ could reshape treatment strategies and drive growth in the ovarian cancer drugs market. Continued focus on novel mechanisms and improved patient survival is expected to remain central to future market development.